Junran Sun

100 Haining Road
Shanghai, 200080, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Enhanced Endocytosis and Mitochondrial Stress Underlie Severe Retinitis Pigmentosa With RHO P347L Mutant.

Enhanced Endocytosis and Mitochondrial Stress Underlie Severe Retinitis Pigmentosa With RHO P347L Mutant.

Journal: Investigative ophthalmology & visual science

Published: July 07, 2026

Large-scale Whole-Exome Sequencing Defines the Protein-Coding Architecture of Retinal Structure, Visual Function, and Major Blinding Diseases.

Large-scale Whole-Exome Sequencing Defines the Protein-Coding Architecture of Retinal Structure, Visual Function, and Major Blinding Diseases.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: May 18, 2026

Clinical and Molecular Characteristics of Foveal Sparing Phenotype in Chinese Patients With Inherited Retinal Diseases.

Clinical and Molecular Characteristics of Foveal Sparing Phenotype in Chinese Patients With Inherited Retinal Diseases.

Journal: Translational vision science & technology

Published: February 17, 2026

Peripheral Retinal Vascular Biomarkers on Ultra-Widefield OCT Angiography for Severity Grading in Retinitis Pigmentosa.

Peripheral Retinal Vascular Biomarkers on Ultra-Widefield OCT Angiography for Severity Grading in Retinitis Pigmentosa.

Journal: American journal of ophthalmology

Published: February 05, 2026

Clinical and Molecular Features of CNGA1-Associated Retinitis Pigmentosa in an East Asian Cohort: Insights for Gene Therapy Trials.

Clinical and Molecular Features of CNGA1-Associated Retinitis Pigmentosa in an East Asian Cohort: Insights for Gene Therapy Trials.

Journal: Ophthalmology science

Published: January 11, 2026

Alu RNA-transfected Primary Mouse Retinal Pigment Epithelium: A Pathologically Relevant In Vitro Model for Age-related Macular Degeneration.

Alu RNA-transfected Primary Mouse Retinal Pigment Epithelium: A Pathologically Relevant In Vitro Model for Age-related Macular Degeneration.

Journal: Journal of visualized experiments : JoVE

Published: November 03, 2025

Seroprevalence of anti-AAV neutralizing antibodiesin healthy and retinitis pigmentosa cohorts: A multi-province study in China.

Seroprevalence of anti-AAV neutralizing antibodiesin healthy and retinitis pigmentosa cohorts: A multi-province study in China.

Journal: Molecular therapy. Advances

Published: October 31, 2025

Geographic and Phenotypic Variability in RHO-Associated Retinopathy: Evidence From a Chinese Cohort and Global Literature.

Geographic and Phenotypic Variability in RHO-Associated Retinopathy: Evidence From a Chinese Cohort and Global Literature.

Journal: American journal of ophthalmology

Published: August 16, 2025

Unveiling Inflammation-Like Retinal Remodeling in CRB1-Associated Inherited Retinal Dystrophies: Insights From a Multicenter Study.

Unveiling Inflammation-Like Retinal Remodeling in CRB1-Associated Inherited Retinal Dystrophies: Insights From a Multicenter Study.

Journal: American journal of ophthalmology

Published: August 07, 2025

Subretinal rAAV2-based VEGF-Trap gene therapy for neovascular age-related macular degeneration: Preclinical assessment and phase 1 trial results.

Subretinal rAAV2-based VEGF-Trap gene therapy for neovascular age-related macular degeneration: Preclinical assessment and phase 1 trial results.

Journal: Cell reports. Medicine

Published: July 21, 2025

Intravitreal Gene Therapy with LX102-C01 in Neovascular Age-Related Macular Degeneration: A Phase I Dose-Escalation Study of 12-Month Safety and Efficacy Outcomes.

Intravitreal Gene Therapy with LX102-C01 in Neovascular Age-Related Macular Degeneration: A Phase I Dose-Escalation Study of 12-Month Safety and Efficacy Outcomes.

Journal: Ophthalmology science

Published: April 28, 2025

Efficacy and Safety of Efdamrofusp Alfa with Personalized Dosing Intervals in Neovascular Age-Related Macular Degeneration: A Phase II Trial.

Efficacy and Safety of Efdamrofusp Alfa with Personalized Dosing Intervals in Neovascular Age-Related Macular Degeneration: A Phase II Trial.

Journal: Ophthalmology science

Published: February 08, 2025

Showing 1-12 of 48

Last Updated: 09/26/2026